Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCompaniesRegulatory risk is only risk that business faces: Lasa Supergenerics

    Regulatory risk is only risk that business faces: Lasa Supergenerics

    In an interview with CNBC-TV18, Omkar P Herlekar, MD of Lasa Supergenerics spoke about the latest happenings in his company and sector. The company manufactures benzimidazole class of active pharmaceutical ingredients (APIs).

    CNBC-TV18
    December 20, 2017 / 14:59 IST

    In an interview with CNBC-TV18, Omkar P Herlekar, MD of Lasa Supergenerics spoke about the latest happenings in his company and sector.

    The company manufactures benzimidazole class of active pharmaceutical ingredients (APIs).

    Capex will be happening on a proportionate basis, he said.

    APIs are bound by foods and drug administration (FDA) regulations and the process to get approvals is tedious, he added.

    According to him, regulatory risk is the only risk that the business faces.

    Right now, we are registered with the Indian Drug Agency and we have filed our DMFs in various countries which includes Europe also, said Herlekar.

    For full interview, watch accompanying video...

    CNBC-TV18
    first published: Dec 20, 2017 02:53 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347